• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature

    2022-12-09 02:52:20ChaLenLeeSpringHolterAyeletBorgidaAnnaDoddStephanieRamotarRobertGrantKristyWassonElenaElimovaRaymondJangMalcolmMooreTaeKyoungKimKoroshKhaliliCarolAnneMoultonStevenGallingerGrainneOKaneJenniferKnox
    World Journal of Gastroenterology 2022年45期

    Cha Len Lee, Spring Holter, Ayelet Borgida, Anna Dodd, Stephanie Ramotar,Robert Grant, Kristy Wasson,Elena Elimova, Raymond W Jang, Malcolm Moore, Tae Kyoung Kim, Korosh Khalili, Carol-Anne Moulton,Steven Gallinger,Grainne M OKane, Jennifer J Knox

    Abstract

    Key Words: Pancreatic acinar carcinoma; BRCA; Polyadenosine diphosphate-ribose polymerase inhibitor;Case report

    INTRODUCTION

    Pancreatic acinar cell carcinoma (PACC) is a rare subtype of pancreatic cancer, accounting for 1%-2% of exocrine pancreatic neoplasms[1]. While there is some clinical and genotype difference, patients with PACC and pancreatic ductal adenocarcinoma (PDAC) are often treated as one disease entity. Evolving data has increased our understanding of this rare tumor’s biology, treatment, and prognosis. Due to the disease’s rarity, most data about PACC are limited to reviews, case reports, and case series. The tumor biology of PACC is not well characterized due to the lack of tissue availability for large-scale molecular analysis. Intriguingly, data obtained in recent years have indicated that PACC has a distinctive mutational landscape[2-4]. There is increasing interest in this area, particularly regarding the homologous repair deficiency (HRD) signature in PACC. Chmieleckiet al[2] reported up to 45%deficiency of the DNA damage repair (DDR) pathway genes in the study population. Oncogenic therapeutic targets includingRAF1rearrangements and mismatch repair genes have proven elusive in a significant proportion of PACCs, and lack of tumor profiling probably contributes to low reporting[3,4].

    Here, we present a PACC case to emphasize the clinical application of genomic profiling in the context of precision medicine for better patient outcomes. Although this patient was very unwell at the presentation, raising the question of suitability for modified FOLFIRINOX (mFFX), the knowledge of theBRCA2likely pathogenic variant (LPV) as predictive for mFFX sensitivity guided our decision to use this regime. In the case series section, we describe the clinical characteristics, therapeutic outcomes, and mutational signatures of additional 10 patients with PACC treated in our center. As proof of concept, we describe the immediate clinical impact for the patients with distinct genomic alterations that have been associated with sensitivity to specific chemotherapeutic or targeted agents.

    CASE PRESENTATION

    Chief complaints

    The patient was a 70 male smoker with recurrent lower limb joint pain and was generally unwell for the previous year.

    History of present illness

    He presented to a rheumatology service with joint pain, which was diagnosed as gout and treated with short courses of prednisolone; however, during the steroid treatment, he also experienced central abdominal discomfort, reduced appetite, and 10 kg weight loss. He had progressive lower joint pain with tender, warm skin nodules, which restricted mobility.

    History of past illness

    He had encephalitis and asthma as a child.

    Personal and family history

    He had a history of transitional cell carcinoma of the renal pelvis at age 46 for which he underwent a left total nephrectomy and a non-small cell lung adenocarcinoma at age 51, which was treated by lung resection. His mother died of ovarian cancer at age 72.

    Physical examination

    Physical examination revealed a cachectic man with a palpable liver edge and ill-defined widespread erythematous subcutaneous nodules on bilateral lower limbs (Figure 1A). Eastern Cooperative Oncology Group performance status (PS) was 2.

    Laboratory examinations

    Initial blood tests demonstrated lipase > 6000 U/dL, elevated transaminases [alanine aminotransferase(ALT) 68 U/L and aspartate aminotransferase 58 U/L], total bilirubin 6 μmol/L, albumin 28 g/L and creatinine 120 μmol/L (estimated glomerular filtration rate 52 mL/min). Tumor markers were: Normal carbohydrate antigen 19-9 (CA19-9) 28 kU/L and raised alpha-fetoprotein 58 μg/L.

    Imaging examinations

    Initial computed tomography (CT) imaging showed a bulky pancreatic tumor measuring over 16 cm and multiple liver metastases. The largest liver lesion measured over 8 cm (Figure 2A). There was an illdefined area of sclerosis in the right ischium which was suspicious of metastasis. Whole-body bone scintigraphy detected mild non-specific increased activity in the right ischium corresponding to the area of sclerosis but no significant bony abnormality. CT chest showed no evidence of thoracic metastases.

    FURTHER DIAGNOSTIC WORK-UP

    The patient underwent a liver biopsy that confirmed a poorly differentiated carcinoma staining positive for keratin 7, CAM5.2, claudin 4, glypican 3, and A1AT. Negative markers included keratin 20, arginase 1, hepPar1, synaptophysin, chromogranin, CD56, and TTF1. The tumor was mismatch repair proficient.An additional skin biopsy of one of the subcutaneous nodules confirmed pancreatic lobular panniculitis.Germline testing identified aBRCA2LPV (c.4356delinsCA, p. Gln1452Hisfs*8).

    CASE SERIES

    Population and clinical data

    We treated 11 PACC patients between August 2014 and July 2021 at Princess Margaret Cancer Centre(PMCC), Toronto. These comprised 6 (55%) pure and 5 (45%) mixed PACC. Approximately 2000 pancreatic carcinoma patients were managed at PMCC during this period. The median age at diagnosis of the PACC patients was 65 years (range 57-74) and all were male. At diagnosis, 2 (18%) were resectable, 2 (18%) locally advanced, and 7 (64%) metastatic. The full demographic features of all patients are summarized in Table 1.

    Four (36%) patients had curative-intent surgery. Three of them developed systemic relapse and received subsequent treatment with palliative chemotherapy. All seven metastatic patients had chemotherapy. Altogether, ten patients received palliative chemotherapy: mFFX (6), Gemcitabine plus Nab-paclitaxel (GnP) (3), and Gemcitabine (1).

    The median time to progression from the date of surgery to the first systemic relapse for the resected patients was 10.5 mo (1.5-10.6). After a follow-up period of 20.4 mo, 6 (55%) patients had died of the disease while five are still alive. The median overall survival (OS) of the cohort was 20.4 mo (range 4.6-36.0) but this variable is temporally immature. The median OS of the four resected patients was 30.3 mo(28.2-36.0).

    Genomic data

    Eligibility for germline genetic testing in Ontario has evolved with the advent of next-generation sequencing, newly identified genes, and the association of established genes with different cancer types.In April 2021, Ontario Health expanded the availability of germline testing to all individuals with pancreatic cancer regardless of age or family history[5]. Before this, germline testing for individuals with pancreatic cancer was based on personal and family history as well as the age of onset. The gene(s)or multi-gene panels performed for patients are based on the individuals’ personal and family history at the time of the initial genetic counseling.

    Table 1 Clinicohistopathologic features of the pancreatic acinar cell carcinoma patients in this dataset (n = 11)

    Seven patients in our case series had clinical germline testing. Four patients did not have germline testing, as they did not meet eligibility criteria based on family history at the time of their diagnosis.Germline PV/LPV was identified in four patients [2BRCA2(18%),1ATM(9%), 1CDKN2A(9%)]. Two(18%) patients had somatic testing with whole-genome sequencing and RNA sequencing as part of clinical trial participation. Identified somatic variants were SND1-BRAFfusion in one patient andKRAS,SMAD4,CDKN2A,ATM,TP53,TGFBR2, andKDM6Ain another patient.

    In terms of actionability, we identified two patients withBRCA2PV/LPV (18%) and oneSND1-BRAFfusion (9%). The first patient carrying a germlineBRCA2LPV is described in this case report. The second patient carrying a germlineBRCA2PV had advanced acinar neuroendocrine carcinoma. Briefly,he was commenced on a combination of 5 FU and Oxaliplatin with a dose reduction (30%) due to comorbidities. Despite this, the evaluation CT scan following 8 cycles of chemotherapy showed a partial response of the primary tumor (63% smaller than baseline) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. He continued additional 4 cycles with further tumor regression, followed by resection. The tumor was pathologic near complete treatment response.

    The patient harboring anSND1-BRAFfusion was commenced on first line GnP. The evaluation CT scans following 6 cycles of chemotherapy showed a significant partial response (55% decrease than baseline) of the primary tumor and lymph nodes as per RECIST1.1. After 16 cycles of GnP, he developed progressive disease and was switched to single-agent Cobimetinib as part of clinical trial participation.Molecular profiling was negative for other key driver mutationsKRAS, TP53, CDKN2A, SMAD4, andBRCAin this patient. Full mutational profiles of the patients and treatment history are outlined in Table 2.

    Table 2 Germline and somatic molecular profiles of the pancreatic ductal adenocarcinoma patients in this study

    TTP: Time to progression; OS: Overall survival; MMR IHC: Mismatch repair immunohistochemistry; mFFX: Modified FOLFIRINOX; GnP: Gemcitabine with Nab-paclitaxel; BSC: Best supportive care; PD: Progressive disease; DOD:Dead of disease; SD: Stable disease; PR: Partial response; AWD: Alive with the disease; WGS: Whole genome sequencing; RNA seq: RNA sequencing; PDAC: Pancreatic ductal adenocarcinoma; NSCLA: Non-small cell lung adenocarcinoma.

    FINAL DIAGNOSIS

    These findings were compatible with PACC with panniculitis, hepatic metastases, and indeterminate bony involvement. Histology revealed no concurrent existence of ductal adenocarcinoma, neuroendocrine or mixed tumor of the pancreas.

    TREATMENT

    The initial plan was to treat the patient with GnP in consideration of his poor PS. However, this decision was changed to the mFFX regimen following the documentation of the germlineBRCA2LPV. mFFX was administered every 2-wk with an additional 20% dose reduction of Oxaliplatin and Irinotecan(Oxaliplatin 65 mg/m2, Irinotecan 120 mg/m2, Fluorouracil 4200 mg/m2and Folinic acid 400 mg/m2).The chemotherapy calculations were based on a body surface area of 1.77 m2.

    Figure 1 Panniculitis is a skin manifestation that can be detected in up to 45% of patients before the recognition of pancreatic disease. A:The widespread ill-defined erythematous tender skin nodules and/or plaques that develop on the shins and around the ankles of our patient as the initial clinical presentation; B: Complete resolution of the panniculitis in our patient after 4 cycles of modified FOLFIRINOX, suggestive of early clinical response.

    Figure 2 Comparison of serial computed tomography images of our patient during chemotherapy. A: Initial axial post-contrast computed tomography (CT) scan shows a large heterogeneous solid mass in the pancreatic tail (short arrows) and a hypoattenuating metastatic liver mass (long arrow); B:Post-chemotherapy axial CT scan performed after 11 cycles of chemotherapy demonstrates marked interval reduction in the size of the pancreatic mass (arrows) and metastatic liver mass (not visible in this image).

    OUTCOME AND FOLLOW-UP

    After the first cycle of mFFX, the patient was hospitalized due to fever, confusion, and worsening polyarthritis. A full septic screen revealed no clear infectious etiology. CT brain showed no brain abnormality. X-rays of several joint areas including sacroiliac joints showed no radiographic evidence of osteomyelitis or septic arthritis. A left knee joint aspiration revealed an inflammatory synovial fluid with elevated white blood cell count, but no growth of infectious organisms and negative for crystal arthropathy. Rheumatoid factor and anti-cyclic citrullinated peptide levels were negative. The rheumatology team believed the patient’s inflammatory seronegative arthritis was paraneoplastic in nature. The patient also displayed clinical adverse events consistent with steroid-induced psychosis, due to the concurrent prednisolone and dexamethasone use. He was started on Naproxen with a tapering dose of prednisolone (from 15 mg daily). His condition improved within a week time and chemotherapy was resumed. Two months after starting mFFX, CT evaluation (post 4 cycles of chemotherapy)showed a 56% partial response based on RECIST1.1. The patient had a marked improvement in symptomatology and panniculitis (Figure 1B). His PS also improved to 0. He continued to tolerate mFFX with grade 1 peripheral sensory neuropathy of hands and feet. Another CT (post 8 cycles of chemotherapy)showed further tumor shrinkage in the primary tumor and hepatic metastases. The sclerotic bone lesion was unchanged in the interval. As the patient was getting a deepening partial response and tolerating mFFX, the chemotherapy was repeated for a total of 11 cycles. A CT imaging at that time point showed further tumor regression in the pancreatic tumor and the hepatic metastases, totaling a 70% decrease from baseline (Figure 2B). The biochemical response was also seen with a CA19-9 level of 17 kU/L.

    After 11 cycles of mFFX, we decided to stop chemotherapy due to the accumulative neurotoxicity.Considering the germlineBRCA2LPV, we elected a therapeutic switch to Olaparib, a polyadenosine diphosphate-ribose polymerase inhibitor (PARPi), as maintenance therapy. He was started on Olaparib 150 mg twice daily dosing that was adjusted for his renal function. At the time of this writing, the patient experienced disease stability for 5 mo with Olaparib, which is ongoing. He tolerates Olaparib with grade 1 fatigue but has no major side effects. He is on monthly follow-ups.

    DISCUSSION

    PACC typically presents in the younger population with a median age of 62 years old. It is more frequent in males, with a male-to-female ratio of 2.3:1[6-8]. The majority (50%-60%) present at an advanced stage, with a median tumor size of 7 cm, and lesions smaller than 2 cm are rarely detected[6-10]. Some cases present with mixed differentiation including mixed acinar-ductal and mixed acinarneuroendocrine subtypes. As the tumor is predominantly found in the tail of the pancreas, patients do not usually present with biliary obstruction, and elevation of CA19-9 is not typically seen[3,11].However, there have been reports of elevated alpha-fetoprotein in younger patients[7,8]. In extreme cases, up to 10%, of patients have lipase hypersecretion which leads to systemic fat necrosis with eosinophilia, erythematous subcutaneous nodules, and polyarthralgia[6,7,9,10]. This paraneoplastic syndrome,also known as Schmid’s triad, is often associated with a poor prognosis[12-15]. The prognosis of PACC is slightly better than that for PDAC[6]. In comparison, 5-year OS for PACC was 42.8%vsPDAC 3.8%[16]. In this study, we analyzed the full clinical characteristics, therapeutic outcomes, and mutational signatures of 11 patients with PACC treated at our center. Based on our analysis, the median OS across all stages is 20.4 mo and 30.3 mo among the resected patients.

    Available literature suggests that over one-third of PACC patients harbor potentially druggable alterations such asBRCA2, PALB2, ATM,BRAF,andJAK1[17]. We observed only one PACC with somaticKRASmutation (9%). This result may be limited by the incomplete somatic testing rate in this study. In distinction to PDAC which is associated withKRASdriver mutations in more than 93% of cases,KRASmutations occur at a much lower prevalence in the acinar/mixed neuroendocrine tumor(9%)[18-21]. While it is difficult to generalize as pancreatic carcinoma is a complex heterogeneous disease, a strong argument can be made that the lack of mutatedKRASidentifies a cohort rich in targetable alterations including fusions, and should have access to integrative germline and somatic sequencing[22].

    Multiple studies including a large series reported by Chmieleckiet al[2] involving 44 PACCs reported a 45% deficiency of DDR pathway genes[3,4,23]. These are inclusive of deficiencies in theBRCApathway and mismatch repair. Combined results suggested that approximately 23% of PACCs are enriched with fusion rearrangements involvingBRAForRAF1genes[2,19]. It appears that PACC subgroups that are lackingRAF1rearrangements (i.e.,fusion-negative tumors) were significantly enriched for deficiency in HRD, and both tumor types are mutually exclusive[2]. Conceptually, these“fusion-negative” tumors can serve as a beneficial demarcation in over two-thirds of PACC patients who may be candidates for platinum-based chemotherapy. PACC withBRCA1/2variants have greater sensitivity to platinum-based chemotherapy and demonstrate significantly better OS than when treated with non-platinum agents[24]. Platinum chemotherapy drugs exert their cytotoxic effect by binding directly to DNA, causing crosslinking of DNA strands and thereby inducing DNA double-strand breaks, which also are ineffectively repaired in cells lacking functioningBRCA1/2. Both the patients in our case series with germlineBRCA2PV/LPV had substantial radiographic regression despite dose reduced Oxaliplatin. Although our patient described in the case report was very unwell with poor PS at presentation, raising the question of suitability for mFFX, the knowledge of theBRCA2LPV as predictive for platinum sensitivity guided our decision to use this regime and resulted in his improved outcome. The other patient was successfully downsized to enable the Whipple procedure for curative intent. Notably, we identified one patient withSND1-BRAFkinase fusion in our case series. Germline and somatic testing were negative forBRCA1orBRCA2in this patient. This particular variant fusion joinsSND1exons 1-10 withBRAFexons 11-18 and maintains the reading frame. It is worth noting that this particular configuration is the most prevalent gene fusion described in melanoma, thyroid, and lung cancers. It has also been reported in PACC[2]. This novel fusion is potentially targetable with MEK inhibitors, such as Trametinib and Cobimetinib[2,25].

    Germline testing and tumor sequencing results are invaluable in identifying PACC patients for treatment regime determination and predictive biomarkers for investigational targeted therapies[14,22,23,26,27]. Newly diagnosed patients with PACC should undergo germline genetic testing and somatic profiling where appropriate, given the high frequency of pathogenic germlineBRCAalterations in PACC. This should be made available to patients regardless of clinical presentation, the pattern of metastases, and pre-existing co-morbidities. This is also consistent with NCCN American Society of Clinical Oncology guidelines which recommend all PDAC patients have upfront germline testing as part of the evolving precision strategy and screening strategies[28]. Similar to numerous studies, our patients with pathogenicBRCA1/2variants have an increased risk of pancreatic, ovarian, breast, and other cancers (Table 2). The lifetime risk for pancreatic cancer inBRCA1andBRCA2mutant carriers is 1% and 4.9%, respectively[29,30]. Unlike breast and ovarian cancers, germlineBRCA1/2mutations alone do not pose a significant risk of pancreatic cancers. Recent literature review showsBRCA2confer to 5%-17% of familial pancreatic cancers (FPC) andBRCA1is not as highly prevalent[31-34]. Studies show that germline susceptibility gene mutations were not found in 80% of pancreatic cancer individuals with strong family history[31,35]. Therefore, comprehensive genome sequencing is needed to identify new possible deleterious genes associated with FPC.

    There are no current clinical practice algorithms for PACC, and it is treated in the same way as PDAC. Although FOLFIRINOX represents the standard treatment with the highest efficacy in PDAC, it is not well studied in PACC[36]. Since 2010, there is a recognized OS benefit to platinum-based agents compared to Gemcitabine or Capecitabine-based regimens, and current therapeutic approaches of metastatic PACCs utilize more FOLFOX or FOLFIRINOX. Furukawaet al[37] described a PACC patient with aBRCA2PV who received Cisplatin after a recurrence of liver metastasis and had a complete remission of the recurring tumor. Ploquinet al[38] reported a PACC patient with aBRCA2PV who experienced a 14-year complete remission following nine cycles of GEMOX, without surgical intervention. Therefore, Cisplatin and GEMOX may be alternatives in patients harboring deficiencies in DDR genes who are unfit for FOLFIRINOX.

    Due to accumulative neurotoxicity after 11 cycles of mFFX, our patient decided to stop systemic chemotherapy completely and de-escalated to Olaparib as a maintenance approach. The use of PARPi in PACC patients with germlineBRCA1orBRCA2PV/LPV is anecdotal[2,23,26]. Furthermore, the updated analysis of the POLO trial showed a lack of OS benefit and quality of life improvement in their Olaparib-treated patients compared to the placebo arm[39]. Despite the aforementioned, we believe that metastatic PACC patients with confirmed HRD phenotype and demonstrated strictly defined platinum sensitivity that involved exceptional response after 16 wk of chemotherapy should be considered for the benefit of PARPi, as the case described.

    Like PDAC, surgery offers the best treatment approach for improved long-term survival[11,16,40].The combination of surgical approach and perioperative chemotherapy in PACC is mainly adapted from the PDAC practice[40-42]. As mentioned, our patient with metastatic germlineBRCA2PV had remarkable tumor downstaging following mFFX, underwent curative surgery, and achieved a pathologic near complete treatment response. Optimizing treatment approaches from this standpoint,with growing access to germline and somatic profiling, should also be further explored in PACC.

    CONCLUSION

    Although it is a rare disease, it is important to identify both common and rare actionable variants in PACCs. In PACC patients withBRCAvariants, the maintenance treatment of PARPi after effective platinum-based chemotherapy should be explored further. Surgical resection may provide the chance of cure after induction chemotherapy in very well-selected patients, particularly in patients withBRCAvariants. Further large-scale studies are required to verify these therapeutic strategies for PACC patients.

    ACKNOWLEDGEMENTS

    We acknowledged Dr. Thiago Muniz’s contribution to reviewing this manuscript for grammar and syntax.

    FOOTNOTES

    Author contributions:Lee CL contributed to the data investigation, writing, and editing of the original draft; Holter S participated in the genomics data curation and revision of the final manuscript; Borgida A, Dodd A and Ramotar S involved in the data acquisition and curation; Kim TY and Khalili K participated in the radiological investigation;Grant R, Elimova E, Wasson K, Jang RW, Moore M, and Moulton CA read and approved the final manuscript;Gallinger S and O’Kane GM reviewed and edited the manuscript; Knox JJ supervised the project and final manuscript revision.

    Informed consent statement:Informed consent is obtained from all participants. Written informed consent is obtained from the patient to publish the case report and accompanying images.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    CARE Checklist (2016) statement:The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:Canada

    ORCID number:Cha Len Lee 0000-0002-3919-7539.

    S-Editor:Wang JJ

    L-Editor:A

    P-Editor:Wang JJ

    亚洲av熟女| 国产黄片美女视频| 少妇人妻一区二区三区视频| 亚洲性夜色夜夜综合| 人人妻,人人澡人人爽秒播| 久久久久久久久久黄片| 国产高清有码在线观看视频| 亚洲欧美精品综合久久99| 国内精品久久久久精免费| 看十八女毛片水多多多| 少妇丰满av| 深爱激情五月婷婷| 国产精品亚洲av一区麻豆| 国产欧美日韩精品一区二区| 在线天堂最新版资源| 搡老岳熟女国产| 国产欧美日韩精品亚洲av| 俄罗斯特黄特色一大片| 亚洲aⅴ乱码一区二区在线播放| 噜噜噜噜噜久久久久久91| 悠悠久久av| 日韩中文字幕欧美一区二区| 麻豆成人av在线观看| 国产免费男女视频| 欧美乱色亚洲激情| 国产伦一二天堂av在线观看| 啦啦啦观看免费观看视频高清| 高清在线国产一区| 精品日产1卡2卡| 少妇人妻精品综合一区二区 | 国产午夜精品久久久久久一区二区三区 | 能在线免费观看的黄片| 国产乱人伦免费视频| 9191精品国产免费久久| 淫妇啪啪啪对白视频| 丰满人妻熟妇乱又伦精品不卡| 精品99又大又爽又粗少妇毛片 | 一级作爱视频免费观看| 欧美成人a在线观看| 精品免费久久久久久久清纯| 18禁在线播放成人免费| 欧美一区二区亚洲| a在线观看视频网站| 一本久久中文字幕| 成人无遮挡网站| 最近最新免费中文字幕在线| 两个人视频免费观看高清| 69av精品久久久久久| 狠狠狠狠99中文字幕| 丝袜美腿在线中文| 99国产综合亚洲精品| 国产精品爽爽va在线观看网站| 国产一区二区在线av高清观看| 美女黄网站色视频| 亚洲国产欧洲综合997久久,| or卡值多少钱| 俄罗斯特黄特色一大片| 99国产精品一区二区蜜桃av| 色精品久久人妻99蜜桃| www.999成人在线观看| 亚洲18禁久久av| 亚洲在线观看片| 高清在线国产一区| 直男gayav资源| 毛片一级片免费看久久久久 | 成年版毛片免费区| 国内精品一区二区在线观看| 人妻制服诱惑在线中文字幕| 在线观看66精品国产| 亚洲人成网站在线播放欧美日韩| 国产视频一区二区在线看| 成人欧美大片| netflix在线观看网站| 91在线观看av| 国产精品98久久久久久宅男小说| 搡女人真爽免费视频火全软件 | 少妇被粗大猛烈的视频| 18美女黄网站色大片免费观看| 又爽又黄a免费视频| 久久国产精品影院| 国产一区二区在线av高清观看| 日韩 亚洲 欧美在线| 看黄色毛片网站| 久久久久亚洲av毛片大全| 色综合站精品国产| 国产精品伦人一区二区| 天天一区二区日本电影三级| www.色视频.com| 国产成人影院久久av| 亚洲av成人精品一区久久| 在线播放无遮挡| 全区人妻精品视频| 久久欧美精品欧美久久欧美| 波多野结衣高清无吗| 精品久久久久久,| 国产主播在线观看一区二区| 丰满人妻一区二区三区视频av| 国产成年人精品一区二区| 女生性感内裤真人,穿戴方法视频| 免费观看人在逋| 性色avwww在线观看| 欧美日韩福利视频一区二区| 99久久精品国产亚洲精品| 欧美高清性xxxxhd video| 日日夜夜操网爽| 欧美乱色亚洲激情| 日韩人妻高清精品专区| 亚洲性夜色夜夜综合| 成年女人毛片免费观看观看9| 在线十欧美十亚洲十日本专区| 一a级毛片在线观看| 中国美女看黄片| 亚洲人成网站高清观看| av天堂在线播放| 欧美日韩乱码在线| 精品人妻一区二区三区麻豆 | 久久人妻av系列| 日本黄色视频三级网站网址| 90打野战视频偷拍视频| 亚洲第一欧美日韩一区二区三区| 亚洲精品在线美女| 国产精品自产拍在线观看55亚洲| 免费黄网站久久成人精品 | 成人性生交大片免费视频hd| 两性午夜刺激爽爽歪歪视频在线观看| 亚洲av.av天堂| 久久性视频一级片| 欧美最黄视频在线播放免费| 少妇人妻一区二区三区视频| 日本免费a在线| 别揉我奶头~嗯~啊~动态视频| 亚洲精品乱码久久久v下载方式| 亚洲第一电影网av| 中文字幕av在线有码专区| 成年女人看的毛片在线观看| 五月伊人婷婷丁香| 十八禁网站免费在线| 黄色视频,在线免费观看| 亚洲欧美清纯卡通| 午夜激情福利司机影院| 亚洲男人的天堂狠狠| 日日夜夜操网爽| 久久精品国产亚洲av涩爱 | 免费电影在线观看免费观看| 超碰av人人做人人爽久久| 俺也久久电影网| 色综合欧美亚洲国产小说| 亚洲经典国产精华液单 | 国产激情偷乱视频一区二区| 日韩欧美精品v在线| 欧美在线一区亚洲| 国内精品久久久久精免费| 国产精品久久久久久亚洲av鲁大| 毛片一级片免费看久久久久 | 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 国产av在哪里看| 欧美精品国产亚洲| 精品人妻熟女av久视频| 成人一区二区视频在线观看| 色哟哟哟哟哟哟| 免费电影在线观看免费观看| 欧美成人一区二区免费高清观看| 亚洲久久久久久中文字幕| 亚洲一区二区三区不卡视频| 国产精品一区二区性色av| 久久久久久国产a免费观看| 欧美日韩福利视频一区二区| 国产综合懂色| 国产视频一区二区在线看| av国产免费在线观看| 欧美成狂野欧美在线观看| 久久精品国产亚洲av天美| 国产毛片a区久久久久| 一a级毛片在线观看| 两个人视频免费观看高清| 国产69精品久久久久777片| 国产成人啪精品午夜网站| 国产av麻豆久久久久久久| 少妇熟女aⅴ在线视频| ponron亚洲| 丁香欧美五月| АⅤ资源中文在线天堂| 18美女黄网站色大片免费观看| 亚洲av免费高清在线观看| 欧美日韩福利视频一区二区| 蜜桃久久精品国产亚洲av| 少妇的逼水好多| 免费在线观看日本一区| 免费在线观看日本一区| 免费av不卡在线播放| 一个人看的www免费观看视频| 久久这里只有精品中国| 在线免费观看不下载黄p国产 | 精品人妻1区二区| 听说在线观看完整版免费高清| 亚洲成av人片免费观看| 人妻久久中文字幕网| 欧美潮喷喷水| 九九在线视频观看精品| 国产一区二区在线观看日韩| 亚洲内射少妇av| 成人无遮挡网站| 成人鲁丝片一二三区免费| 免费一级毛片在线播放高清视频| 一级黄色大片毛片| 欧美在线黄色| 女生性感内裤真人,穿戴方法视频| 一区二区三区免费毛片| 国产成人欧美在线观看| 午夜视频国产福利| 国语自产精品视频在线第100页| 最好的美女福利视频网| 国产私拍福利视频在线观看| 国产黄色小视频在线观看| 熟女人妻精品中文字幕| 十八禁国产超污无遮挡网站| 我的老师免费观看完整版| 亚洲av美国av| 亚洲精华国产精华精| 午夜福利成人在线免费观看| 99久久99久久久精品蜜桃| 日韩精品中文字幕看吧| 亚洲乱码一区二区免费版| 高清日韩中文字幕在线| 性插视频无遮挡在线免费观看| 欧洲精品卡2卡3卡4卡5卡区| 午夜福利18| 国产亚洲精品久久久com| 国产免费男女视频| 九九热线精品视视频播放| 丰满人妻熟妇乱又伦精品不卡| 日韩精品青青久久久久久| 欧美成人一区二区免费高清观看| 欧美高清成人免费视频www| 他把我摸到了高潮在线观看| 精品日产1卡2卡| 国产爱豆传媒在线观看| a在线观看视频网站| 成人永久免费在线观看视频| 久久久久久久午夜电影| 男女那种视频在线观看| 国产主播在线观看一区二区| 成年女人毛片免费观看观看9| 三级国产精品欧美在线观看| 综合色av麻豆| xxxwww97欧美| 成人永久免费在线观看视频| 亚洲精品成人久久久久久| 一个人免费在线观看电影| 免费观看的影片在线观看| 精品午夜福利视频在线观看一区| 国产午夜精品论理片| 亚洲美女黄片视频| 两个人视频免费观看高清| 久久草成人影院| 国产精品电影一区二区三区| 欧美三级亚洲精品| 村上凉子中文字幕在线| 在线观看美女被高潮喷水网站 | 怎么达到女性高潮| 国产午夜福利久久久久久| 国产精品女同一区二区软件 | 日本黄色视频三级网站网址| 嫩草影院入口| 又黄又爽又免费观看的视频| 免费观看人在逋| 九色国产91popny在线| 18禁黄网站禁片免费观看直播| 久久久色成人| 成人特级黄色片久久久久久久| 91在线精品国自产拍蜜月| 波多野结衣巨乳人妻| 宅男免费午夜| 黄色丝袜av网址大全| 人人妻人人澡欧美一区二区| av女优亚洲男人天堂| 成年版毛片免费区| 天美传媒精品一区二区| 日韩欧美在线乱码| 亚洲国产欧洲综合997久久,| www.熟女人妻精品国产| 婷婷色综合大香蕉| 一级av片app| 又粗又爽又猛毛片免费看| 一边摸一边抽搐一进一小说| 国语自产精品视频在线第100页| 黄色视频,在线免费观看| 国产探花在线观看一区二区| 国产精品免费一区二区三区在线| 亚洲国产精品久久男人天堂| 日韩欧美精品v在线| 国产精品美女特级片免费视频播放器| 亚洲精品在线美女| 在线观看午夜福利视频| 在线观看66精品国产| 国产精品自产拍在线观看55亚洲| 国产欧美日韩精品一区二区| 色吧在线观看| 黄色丝袜av网址大全| 亚洲欧美日韩无卡精品| 亚洲人与动物交配视频| 精品人妻偷拍中文字幕| 可以在线观看的亚洲视频| 久久精品91蜜桃| 欧美黑人巨大hd| 国产成+人综合+亚洲专区| 九色成人免费人妻av| 国产 一区 欧美 日韩| 日韩中字成人| 69av精品久久久久久| 午夜免费男女啪啪视频观看 | 日本 av在线| 97超级碰碰碰精品色视频在线观看| 亚洲中文字幕一区二区三区有码在线看| 久久6这里有精品| 在线国产一区二区在线| 淫秽高清视频在线观看| 18+在线观看网站| 亚洲av美国av| 精品久久久久久久久久免费视频| 国内揄拍国产精品人妻在线| 国产精品伦人一区二区| 丁香欧美五月| 91麻豆av在线| 一级a爱片免费观看的视频| xxxwww97欧美| 日本与韩国留学比较| 51国产日韩欧美| 色哟哟哟哟哟哟| 嫁个100分男人电影在线观看| 黄色配什么色好看| 两个人视频免费观看高清| 国产午夜精品论理片| 九九热线精品视视频播放| 99热精品在线国产| 欧美黑人欧美精品刺激| 国产精品永久免费网站| 他把我摸到了高潮在线观看| 亚洲天堂国产精品一区在线| 免费av毛片视频| 色av中文字幕| 国产一区二区在线观看日韩| 成年免费大片在线观看| 亚洲乱码一区二区免费版| 中文字幕精品亚洲无线码一区| 国产精品综合久久久久久久免费| 青草久久国产| 国产极品精品免费视频能看的| 久久天躁狠狠躁夜夜2o2o| 99国产精品一区二区三区| 欧美一区二区亚洲| 中文资源天堂在线| 天美传媒精品一区二区| 亚洲国产精品合色在线| 亚洲欧美日韩卡通动漫| 欧美精品啪啪一区二区三区| 搡老妇女老女人老熟妇| 久久久久国产精品人妻aⅴ院| 在线观看美女被高潮喷水网站 | 亚洲精品粉嫩美女一区| 国产精品电影一区二区三区| 琪琪午夜伦伦电影理论片6080| 99热精品在线国产| 丰满乱子伦码专区| 中文字幕高清在线视频| 亚洲性夜色夜夜综合| 18+在线观看网站| 亚洲av电影在线进入| 中文字幕av在线有码专区| 成人特级av手机在线观看| 天堂av国产一区二区熟女人妻| 国产一区二区在线av高清观看| 成人一区二区视频在线观看| 久久精品综合一区二区三区| 少妇的逼水好多| 淫秽高清视频在线观看| 国产精品亚洲美女久久久| 最近视频中文字幕2019在线8| 国产精品人妻久久久久久| 久久久久久大精品| 91狼人影院| 日韩欧美免费精品| 国产精品一区二区三区四区免费观看 | 成年女人看的毛片在线观看| 亚洲成av人片免费观看| 精品国产亚洲在线| 在线观看午夜福利视频| 国产一级毛片七仙女欲春2| 午夜免费激情av| 久久国产精品影院| 国产黄色小视频在线观看| 校园春色视频在线观看| 嫩草影院精品99| 国产精品永久免费网站| ponron亚洲| 色播亚洲综合网| 免费观看精品视频网站| 亚洲第一区二区三区不卡| 亚洲国产欧美人成| 亚洲一区高清亚洲精品| 久久久久国产精品人妻aⅴ院| 亚洲精品在线观看二区| 九九热线精品视视频播放| 成熟少妇高潮喷水视频| 精品国产亚洲在线| 69人妻影院| 国产高清三级在线| 欧美又色又爽又黄视频| 日日干狠狠操夜夜爽| 亚洲人成网站在线播| 神马国产精品三级电影在线观看| 少妇裸体淫交视频免费看高清| av黄色大香蕉| 波多野结衣高清无吗| 亚洲精品影视一区二区三区av| 亚洲人成网站高清观看| 亚洲va日本ⅴa欧美va伊人久久| 国产精品久久久久久精品电影| 久9热在线精品视频| 国产熟女xx| 高清日韩中文字幕在线| 最新在线观看一区二区三区| 欧美三级亚洲精品| 日韩av在线大香蕉| 在线观看舔阴道视频| 一本综合久久免费| 一a级毛片在线观看| 国产欧美日韩一区二区精品| 成人高潮视频无遮挡免费网站| 97超视频在线观看视频| 亚洲一区高清亚洲精品| 日本黄大片高清| 岛国在线免费视频观看| 赤兔流量卡办理| 久久婷婷人人爽人人干人人爱| bbb黄色大片| 国产探花极品一区二区| a级毛片免费高清观看在线播放| 级片在线观看| 午夜福利18| 日韩亚洲欧美综合| 亚洲一区二区三区不卡视频| 久久久久久久午夜电影| av在线老鸭窝| 国产一区二区在线观看日韩| 99在线视频只有这里精品首页| 人妻夜夜爽99麻豆av| 无人区码免费观看不卡| av国产免费在线观看| www.熟女人妻精品国产| 亚洲内射少妇av| 久久久久免费精品人妻一区二区| 欧美日韩乱码在线| 国产精品98久久久久久宅男小说| 国产欧美日韩一区二区精品| 亚洲乱码一区二区免费版| 亚洲男人的天堂狠狠| 丰满人妻一区二区三区视频av| 老女人水多毛片| 男女床上黄色一级片免费看| 亚洲第一电影网av| 日本免费一区二区三区高清不卡| 国产三级中文精品| 欧美成狂野欧美在线观看| 搞女人的毛片| 丰满乱子伦码专区| 久久久精品大字幕| 18禁黄网站禁片免费观看直播| 亚洲人成电影免费在线| 欧美最新免费一区二区三区 | 精品人妻一区二区三区麻豆 | 日本免费a在线| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 精华霜和精华液先用哪个| 99精品久久久久人妻精品| 成人永久免费在线观看视频| 麻豆国产97在线/欧美| 国产精品伦人一区二区| 日本免费一区二区三区高清不卡| 国产亚洲精品久久久com| 九九在线视频观看精品| 一区二区三区免费毛片| 国产黄片美女视频| 毛片一级片免费看久久久久 | 欧美潮喷喷水| 国产私拍福利视频在线观看| 亚洲欧美激情综合另类| h日本视频在线播放| 深爱激情五月婷婷| av专区在线播放| 99久久精品热视频| 中文字幕精品亚洲无线码一区| av在线蜜桃| 一本久久中文字幕| .国产精品久久| 中文字幕熟女人妻在线| 亚洲天堂国产精品一区在线| av欧美777| 老司机午夜福利在线观看视频| 国产午夜精品久久久久久一区二区三区 | 欧美另类亚洲清纯唯美| 91av网一区二区| 极品教师在线视频| 日韩欧美精品v在线| 最新在线观看一区二区三区| av在线观看视频网站免费| 欧美色欧美亚洲另类二区| 久久欧美精品欧美久久欧美| 51国产日韩欧美| 97碰自拍视频| 99热6这里只有精品| 久久精品人妻少妇| 老司机午夜十八禁免费视频| 欧美日本亚洲视频在线播放| 亚洲激情在线av| 美女高潮的动态| 日本免费a在线| 国模一区二区三区四区视频| 亚洲精品456在线播放app | 在线观看美女被高潮喷水网站 | 免费搜索国产男女视频| 亚洲无线在线观看| 日日干狠狠操夜夜爽| 国产麻豆成人av免费视频| 精品国内亚洲2022精品成人| 精品一区二区三区人妻视频| 日韩欧美三级三区| 国产精品亚洲av一区麻豆| 精品国产三级普通话版| 淫妇啪啪啪对白视频| 黄色视频,在线免费观看| 国产精品国产高清国产av| 亚洲五月婷婷丁香| 欧美又色又爽又黄视频| 亚洲欧美精品综合久久99| 久久精品国产自在天天线| 一本精品99久久精品77| 女生性感内裤真人,穿戴方法视频| 中文资源天堂在线| 国产精品久久久久久人妻精品电影| 亚洲中文字幕一区二区三区有码在线看| 一进一出抽搐动态| eeuss影院久久| 亚洲av成人精品一区久久| 国产黄a三级三级三级人| 国产免费男女视频| 午夜福利视频1000在线观看| 日韩欧美 国产精品| 最新在线观看一区二区三区| 一进一出好大好爽视频| 精品久久久久久久人妻蜜臀av| 免费搜索国产男女视频| 日韩欧美 国产精品| 欧美极品一区二区三区四区| 亚洲真实伦在线观看| 桃红色精品国产亚洲av| 久久国产精品人妻蜜桃| 老女人水多毛片| 国产精品一区二区性色av| 欧美一区二区国产精品久久精品| 国产成人欧美在线观看| 欧美不卡视频在线免费观看| 久久亚洲精品不卡| 欧美成狂野欧美在线观看| 色综合欧美亚洲国产小说| 人妻制服诱惑在线中文字幕| 他把我摸到了高潮在线观看| xxxwww97欧美| 熟女电影av网| 欧美日韩乱码在线| 真人做人爱边吃奶动态| 宅男免费午夜| 一级黄片播放器| 好男人电影高清在线观看| 亚洲精品乱码久久久v下载方式| 亚洲精品粉嫩美女一区| 黄色一级大片看看| 日韩有码中文字幕| 国产高清激情床上av| 亚洲中文日韩欧美视频| 97热精品久久久久久| 动漫黄色视频在线观看| 最近视频中文字幕2019在线8| 午夜久久久久精精品| 午夜福利在线观看免费完整高清在 | 亚洲最大成人av| 51国产日韩欧美| 久久精品91蜜桃| 麻豆国产av国片精品| 日本免费一区二区三区高清不卡| 无人区码免费观看不卡| 免费看a级黄色片| 亚洲一区高清亚洲精品| 少妇人妻一区二区三区视频| 精品日产1卡2卡| 男人舔女人下体高潮全视频| 国产成人啪精品午夜网站| 热99在线观看视频| 蜜桃久久精品国产亚洲av| 热99在线观看视频| 天堂影院成人在线观看| 男女床上黄色一级片免费看| 欧美最黄视频在线播放免费| 日韩成人在线观看一区二区三区| x7x7x7水蜜桃| 色在线成人网| 亚洲av电影不卡..在线观看| 久久精品夜夜夜夜夜久久蜜豆| 在现免费观看毛片| 两性午夜刺激爽爽歪歪视频在线观看| av天堂在线播放| 简卡轻食公司| 中文亚洲av片在线观看爽| 欧美一区二区亚洲| 男女那种视频在线观看|